Глобальный рынок микрофлюидики – тенденции отрасли и прогноз до 2031 года

Анализ и размер рынка микрофлюидики

Устройства Lab-on-a-chip представляют собой ключевое приложение рынка микрофлюидики, используя миниатюрные платформы, которые интегрируют различные лабораторные функции в одно микрофлюидическое устройство. Технология Lab-on-a-chip позволяет быстро и эффективно тестировать образцы в компактном и портативном формате, предлагая такие преимущества, как меньшие объемы образцов, более короткое время анализа и более низкие затраты по сравнению с традиционными лабораторными методами. Они находят широкое применение в диагностике на месте оказания помощи, мониторинге окружающей среды, разработке лекарственных препаратов и персонализированной медицине, стимулируя инновации и достижения в здравоохранении и науках о жизни.

Объем мирового рынка микрофлюидики в 2023 году оценивался в 26,65 млрд долларов США, а к 2031 году, по прогнозам, он достигнет 81,57 млрд долларов США, при среднегодовом темпе роста 15,01% в прогнозируемый период с 2024 по 2031 год. Помимо аналитических данных о рыночных сценариях, таких как рыночная стоимость, темпы роста, сегментация, географический охват и основные игроки, рыночные отчеты, подготовленные Data Bridge Market Research, также включают в себя углубленный экспертный анализ, эпидемиологию пациентов, анализ разработки, анализ цен и нормативно-правовую базу.

Область отчета и сегментация рынка       

Market Definition

Microfluidics is a multidisciplinary field that deals with the behavior, manipulation, and control of fluids at the microscale level, typically within channels with dimensions ranging from tens to hundreds of micrometers. It enables precise handling of small fluid volumes, making it valuable for various applications such as lab-on-a-chip devices, point-of-care diagnostics, and drug delivery systems.

Microfluidics Market Dynamics

Drivers

• Growing Advancements in Technology Expand the Scope of Applications for Microfluidics

Continuous innovation in areas such as material science, fabrication techniques, and detection methods drives the evolution of microfluidics technology, leading to the development of increasingly sophisticated microfluidic devices with enhanced capabilities. Advancements in software and automation streamline operation and data analysis, improving efficiency and reliability of microfluidics technology. These technological breakthroughs expand the scope of applications for microfluidics, spanning from healthcare to environmental sectors, and drive market growth by unlocking new opportunities for research, development, and commercialization of microfluidic-based solutions.

For instance, In August 2022, HORIBA's collaboration with SigTuple exemplifies the integration of microfluidics into advanced healthcare solutions. Combining microfluidics with AI, robotics, and cloud computing, SigTuple developed smart diagnostic solutions such as the AI100 for digital pathology. This collaboration underscores the pivotal role of microfluidics in enhancing the accuracy and efficiency of diagnostic processes, further aligning with the broader trend of leveraging technology to drive innovation and accessibility in healthcare.

• Growing Demand for Point-of-Care Diagnostics Increases the Demand for Microfluidic Devices

Point-of-care diagnostics offer rapid and convenient testing directly at the point of patient care, bypassing the need for centralized laboratory facilities and lengthy wait times for results. Microfluidic devices enable the development of compact and portable diagnostic tools that can perform a wide range of tests with high sensitivity and specificity using minimal sample volumes. With an increasing emphasis on early disease detection, remote monitoring, and personalized medicine, the demand for microfluidic-based point-of-care diagnostics continues to surge, driving market expansion.

Opportunities

• Escalating Chronic Diseases Increases the Demand for Microfluidic-Based Diagnostics

The rising prevalence of chronic diseases such as diabetes underscores the urgency for innovative diagnostic and therapeutic solutions. Microfluidic technologies offer a promising avenue, enabling the development of highly sensitive and portable diagnostic devices for early detection and monitoring. With diabetes cases projected to surge in Germany, reaching 6.5 million by 2030 according to IDF statistics, there is a pressing need for novel treatments. Microfluidic electrospray technology presents a viable solution, facilitating the creation of porous microcapsules encapsulating β cells for diabetes treatment. This convergence of rising disease burdens and technological advancements in microfluidics underscores its pivotal role in addressing healthcare challenges and driving market expansion.

• Increased Focus on Tailored Applications Leads to Development of New Microfluidic Products

The collaboration between Loschmidt laboratories and ETH Zurich partners in March 2021 exemplifies the drive for innovation in the microfluidics market. Creating a novel microfluidic platform, the team aims to investigate enzymes and their properties with enhanced efficiency and speed. This development aligns with the broader trend of developing new products in microfluidics to address specific applications, such as drug discovery and enzyme studies. The platform's versatility is showcased by its utilization in developing new thrombolytic for stroke treatment and studying the evolution of bioluminescent enzymes, highlighting its potential impact across diverse fields. Such collaborations underscore the dynamic nature of the microfluidics market, propelled by the pursuit of novel solutions to pressing healthcare and scientific challenges.

Restraints/Challenges

• Complexity of Integrating Microfluidic Technologies into Existing Workflows

Incorporating microfluidic devices into diverse industries such as healthcare, biotechnology, and manufacturing often requires extensive modifications and adaptations to existing processes. Technical challenges, compatibility issues, and the need for specialized infrastructure and expertise further complicate integration efforts. As a result, companies may hesitate to adopt microfluidic solutions, fearing disruptions to operations and potential inefficiencies.

• High Initial Investment Costs Impacting Microfluidic Technologies Implementation

The intricate design and fabrication processes involved in creating microfluidic devices require substantial financial resources for research, equipment, and infrastructure. This financial barrier can be particularly challenging for smaller companies and startups looking to enter the market, as they may struggle to secure the necessary funding. The initial investment costs can deter potential users from adopting microfluidic solutions, especially in industries with budget constraints or uncertain returns on investment. As a result, the high upfront costs associated with microfluidics can impede market growth and limit the widespread adoption of these innovative technologies.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2023, India's Amar Equipment launched NanoMake, a microfluidics-based device aimed at enhancing preclinical research for mRNA vaccines targeting COVID-19. This innovation is anticipated to significantly advance the development of vaccines by streamlining research processes and increasing efficiency, thereby contributing to the broader market growth of microfluidics-based technologies
• In 2022, Standard BioTools, Inc. launched the X9 Real-time PCR system, leveraging microfluidics technology to deliver high efficiency and data output in a single run. This launch expanded the company's product portfolio, catering to the growing demand for advanced genomics instruments, and is expected to bolster its competitive position in the market
• In 2021, Fluidigm launched the Biomark X microfluidics platform, aimed at optimizing laboratory workflows by reducing hands-on time and accelerating results with enhanced data output per run. This innovation reflects Fluidigm's commitment to providing cutting-edge solutions for life sciences research, thereby contributing to market growth and advancing scientific capabilities
• In 2021, SCHOTT's acquisition of Applied Microarrays Inc. bolstered its presence in the U.S. and enhanced its bioscience capabilities. This strategic move enabled SCHOTT to broaden its portfolio of microarray solutions, leveraging Applied Microarrays' expertise to strengthen its position in the rapidly evolving bioscience market

Microfluidics Market Scope

The market is segmented on the basis of product type, material, technology, application, sector and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Microfluidic-based devices
• Microfluidic Components

Material

• Polymer
• Glass
• Silicon
• Metal
• Ceramics
• PDMS
• Other

Technology

• Medical/Healthcare
• Non-medical

Application

• In Vitro diagnostics
• Point-of-Care Testing
• Clinical Diagnostics
• Pharmaceutical Research
• Lab Analytics
• Microdispensing
• Microreaction
• Drug Delivery
• Laboratory Testing
• Analytical Testing
• High Throughput Screening

Sector

• Industrial
• Healthcare
• In-vitro Diagnostics
• Environmental Research
• Clinical Diagnostics

End User

• Hospitals and Diagnostic Centers
• Academic and Research Institutes
• Pharmaceutical and Biotechnology Companies

Microfluidics Market Regional Analysis/Insights

The market is analyzed and market size insights and trends are provided by product type, material, technology, application, sector and end user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates in the market is propelled by its vibrant research landscape, where esteemed institutions drive innovation in novel microfluidic devices. With a rich ecosystem of academic and industrial collaboration, the region fosters cutting-edge research and development initiatives. This synergy between academia and industry cultivates a fertile ground for pioneering advancements, positioning North America as a global leader in microfluidic technologies. As a result, the region consistently produces groundbreaking solutions, attracting significant investments and solidifying its preeminence in this rapidly evolving field.

The Asia-Pacific is expected for rapid growth in the market, primarily due to heightened government backing for infrastructure development and the strengthening of intellectual property rights. This support fosters an environment conducive to innovation and investment, attracting both domestic and foreign capital. As infrastructure improves, it facilitates smoother trade and connectivity, bolstering economic activity across various sectors. Robust intellectual property protections incentivize research and development, fostering a culture of innovation and driving long-term economic expansion in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Microfluidics Market Analysis

Конкурентная среда рынка содержит сведения о конкурентах. Включены сведения о компании, ее финансах, полученном доходе, рыночном потенциале, инвестициях в исследования и разработки, новых рыночных инициативах, глобальном присутствии, производственных площадках и объектах, производственных мощностях, сильных и слабых сторонах компании, запуске продукта, широте и широте продукта, доминировании приложений. Приведенные выше данные касаются только фокуса компаний на рынке.

Некоторые из основных игроков, работающих на рынке:

• Данахер (США)
• Thermo Fisher Scientific Inc. (США)
• PerkinElmer Inc. (США)
• Agilent Technologies Inc. (США)
• Bio-Rad Laboratories Inc. (США)
• БД (США)
• Illumina, Inc. (США)
• Ф. Хоффманн-Ля Рош (Швейцария)
• Корпорация Fluidigm (США)
• Dolomite Microfluidics (Великобритания)
• QIAGEN (Германия)
• Эбботт (США)
• БИОМЕРЬЕ (Франция)
• микрофлюидный ChipShop GmbH (Германия)
• Elveflow (Франция)
• Cellix Bio. (Индия)
• Micronit BV (Нидерланды)
• PARKER HANNIFIN CORP (США)
• Фортив (США)

SKU-10534